Cenova Capital

Cenova Capital, established in 2010, is a Shanghai-based venture capital firm specializing in late-stage and growth equity investments in the life sciences and healthcare sectors in China. It focuses on sub-sectors such as pharmaceuticals, medical technology, healthcare services, precision medicine, e-health, and digital health, including artificial intelligence and big data applications. With five funds under management, Cenova has invested in over 50 companies, facilitating the transformation of China's healthcare system. Its investors are primarily large domestic and international institutional investors.

Tao Huang

Venture Partner and Senior Manager, Project Management (Technology)

Jun Wu Ph.D

Co-Founder, Managing Partner and Chairman

Melissa Zhang

Vice President

Kai Zhao

Managing Partner

49 past transactions

Vivace Therapeutics

Series D in 2025
Vivace Therapeutics, Inc. is a biotechnology company focused on the discovery and development of small molecule therapies aimed at treating cancer. Founded in 2014 and located in the San Francisco Bay Area, the company specializes in targeting the Hippo pathway, which plays a critical role in regulating tissue regeneration and organ size. Vivace Therapeutics employs an innovative approach by leveraging research from leading academic institutions to develop novel therapeutics that can be used independently or in combination with existing treatments. The company is committed to advancing promising drug candidates and therapeutic technologies to address the unmet needs of cancer patients, driven by a mission to improve patient outcomes and quality of life.

Weimai

Series D in 2025
Weimai is a developer of a health application platform that aims to enhance medical and health services. The platform offers various features, including Internet-based appointment scheduling, maternal and child disease management, grading diagnosis and treatment, remote diagnosis, and medical records management. By cooperating with local hospitals, Weimai provides a range of services such as medical consultations, internet diagnosis and treatment, health management, and on-site medical and nursing assistance. This integration not only facilitates access to medical care for patients but also helps hospitals improve their operational efficiency. Ultimately, Weimai's goal is to deliver a comprehensive family doctor application that brings medical expertise into homes.

Haofeng Medtech

Series B in 2025
Haofeng Medtech is a specialized provider of Contract Development and Manufacturing Organization (CDMO) services for interventional medical devices. The company focuses on developing, manufacturing, and organizing these devices to meet specific client needs. Haofeng Medtech has established various wholly-owned subsidiaries to cater to different segments of the CDMO industry chain, aiming to enhance treatment efficiency for its clients.

Agile Medical

Series A in 2024
Agile Medical, a surgical robot company, focuses on research, development, and industrialization of intelligent surgical products. Agile Medical's technology innovation platform covers mechanics, electronics, optics, computing, and software.

JLand Biotech

Series B in 2023
JLand Biotech specializes in the development and manufacturing of Biollagenâ„¢, a non-animal sourced collagen produced through advanced bioengineering techniques like genetic recombination and microbial fermentation. The company aims to become the world's leading supplier of non-animal collagen, catering primarily to industries such as cosmetics and food.

Phage Pharm

Series B in 2023
PhagePharm is a company focused on the industrialization of bacteriophages, specifically developing antibiotics and phage products for the animal breeding industry. The organization creates a range of effective disease immunization solutions aimed at enhancing the health of animals and supporting the growth of the animal breeding and agricultural sectors. By providing innovative health products, PhagePharm aims to improve overall animal health and productivity within these industries.

Eluminex Biosciences

Series B in 2023
Eluminex Biosciences is engaged in the research, development, and commercialization of innovative therapies aimed at addressing unmet medical needs in ocular health. The company focuses on ophthalmology and tissue regeneration, leveraging recombinant human collagen to develop therapeutic solutions. Its pipeline includes treatments designed to slow and mitigate the effects of aging and overuse on vision, ultimately enabling healthcare providers to offer improved care to their patients. Through its commitment to advancing the field of ophthalmology, Eluminex Biosciences seeks to enhance diagnostic and therapeutic options for ocular illnesses.

Pulnovo Medical

Venture Round in 2022
Pulnovo Medical, established in 2013 in Wuxi, Anhui, is focused on the development, production, and service provision of innovative medical technologies. The company specializes in creating advanced equipment for treating pulmonary hypertension, particularly through the use of pulse radiofrequency ablation technology. Its core products include pioneering high-frequency ablation equipment and intravascular catheters, which are protected by global invention patents. Pulnovo Medical aims to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure by offering cutting-edge treatment solutions.

BestCovered

Series A in 2022
BestCovered is a company focused on developing digital screening tools aimed at early detection and intervention for Alzheimer's disease. By leveraging artificial intelligence technologies, including speech analysis, gesture recognition, and natural language processing, BestCovered creates cognitive impairment risk assessment tools. These tools enable hospitals to achieve high prediction accuracy for Alzheimer's, facilitating timely care for patients. Additionally, BestCovered offers systematic multi-dimensional activation courses designed to help individuals maintain a flexible mind, further contributing to cognitive health and well-being.

Hunan Yiyi Pharmaceutical Technology

Series B in 2022
Hunan Yiyi Pharmaceutical Technology develops and operates an online platform for pharmaceutical products. It allows members to purchase various medicines. Hunan Yiyi Pharmaceutical Technology was founded in 2019 and is based in Jiangsu, China.

Huili Bio

Series A in 2022
Huili Bio is a next-generation synthetic biology enzyme computational design platform.

Yuanyin Bio

Series A in 2022
Yuanyin Bio is a biotechnology company focuses on the research and application of circular RNA technology in the field of innovative drugs and therapies, builds a robust pipeline of preventive and therapeutic new drugs, and is dedicated to addressing clinically unmet disease needs. They serve in the field of innovative drugs and therapies. It establishes a pipeline of preventive and therapeutic new drugs and is committed to solving clinically unmet disease needs.

Zhongze Therapeutics

Seed Round in 2022
Zhongze Therapeutics is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies for psychiatric and neurological disorders. The company aims to create transformative drug solutions that address central nervous system diseases, providing effective treatment options to patients. By focusing on cutting-edge research and development, Zhongze Therapeutics seeks to improve outcomes for individuals affected by these complex conditions.

ENSEM Therapeutics

Series A in 2022
ENSEM Therapeutics is a pioneering drug discovery and development company focused on creating innovative small-molecule precision medicines for oncology. Utilizing its proprietary Kinetic Ensemble platform, the company specializes in detecting and characterizing rare conformational states of drug targets, which are crucial for understanding oncogenic processes, regulatory mechanisms, and drug resistance. This approach not only provides new therapeutic opportunities but also allows drug developers to address high-value targets that are typically challenging to target. With potential applications extending beyond oncology to genetic disorders and other disease areas, ENSEM Therapeutics aims to transform the landscape of precision medicine.

Jiandanxinli (aka Simple Psychology)

Series B in 2022
Simple psychology belongs to Beijing Zhujian Technology Co., Ltd. Simple psychology focuses on providing high-quality psychological services.

TreeENT

Series A in 2022
TreeENT Health is a specialized healthcare provider focused on ear, nose, and throat (ENT) services, established in 2017 and headquartered in Hangzhou, China. The company operates a chain of medical centers that cater to a variety of ENT conditions, including suppurative otitis media, allergic rhinitis, chronic sinusitis, and thyroid cancer. TreeENT Health utilizes advanced medical technologies, such as minimally invasive surgical techniques, internet-enabled services, and wearable medical devices, to enhance patient care. Their offerings include diagnostic services like Danish ear hearing detection, nasal endoscopy video examinations, and nasopharyngoscopy, along with personalized chronic disease rehabilitation. The integration of online appointment scheduling through platforms like WeChat facilitates convenient access to expert consultations and treatments, ensuring a high-quality experience for patients.

AnHeart Therapeutics

Series B in 2021
AnHeart Therapeutics is a biopharmaceutical company dedicated to improving the lives of cancer patients through the development of innovative pharmaceutical products. The company focuses on acquiring, developing, and commercializing novel therapies that enhance human health and quality of life. Its primary research product, AB-106, is an oral, highly selective small molecule inhibitor targeting ROS1 and NTRK, aimed at providing precision treatment options for individuals with cancer. Through its pipeline of advanced therapies, AnHeart Therapeutics seeks to enable medical professionals to deliver effective solutions that address critical needs in oncology.

UP Clinic

Series B in 2021
UP Clinic is an orthopedic rehabilitation center specializing in the diagnosis and treatment of sports medicine and musculoskeletal conditions. The clinic caters to sports enthusiasts, orthopedic patients, postoperative individuals, and those experiencing sub-health issues. It offers a comprehensive range of services, including medical treatment, rehabilitation, and specialized orthopedic care. With a team of professional medical experts and advanced equipment, UP Clinic emphasizes a patient-centered approach and adheres to evidence-based medicine, ensuring high-quality care tailored to individual needs.

Yuanyin Bio

Seed Round in 2021
Yuanyin Bio is a biotechnology company focuses on the research and application of circular RNA technology in the field of innovative drugs and therapies, builds a robust pipeline of preventive and therapeutic new drugs, and is dedicated to addressing clinically unmet disease needs. They serve in the field of innovative drugs and therapies. It establishes a pipeline of preventive and therapeutic new drugs and is committed to solving clinically unmet disease needs.

Umai Technology

Series A in 2021
Umai Technology is a skin image management software firm providing image processing, information acquisition, and clinical diagnosis.

magAssist

Series C in 2021
magAssist, founded in 2017 by Dr. Xu Bozhen, is a high-tech enterprise based in Suzhou, specializing in the development of in-vitro artificial heart devices aimed at assisting patients with cardiovascular diseases. The company focuses on creating short-term to medium-term ventricular assist devices that are compatible with various blood types. Utilizing advanced fluid mechanics and magnetic suspension technology, magAssist aims to minimize incompatibility issues in patients, thereby enhancing their recovery and treatment processes. The core team consists of leading experts in artificial heart engineering, leveraging extensive experience in research and development to produce domestically manufactured devices with independent intellectual property rights.

Pulnovo Medical

Venture Round in 2021
Pulnovo Medical, established in 2013 in Wuxi, Anhui, is focused on the development, production, and service provision of innovative medical technologies. The company specializes in creating advanced equipment for treating pulmonary hypertension, particularly through the use of pulse radiofrequency ablation technology. Its core products include pioneering high-frequency ablation equipment and intravascular catheters, which are protected by global invention patents. Pulnovo Medical aims to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure by offering cutting-edge treatment solutions.

Umai Technology

Series A in 2021
Umai Technology is a skin image management software firm providing image processing, information acquisition, and clinical diagnosis.

VivaVision Biotech

Series D in 2021
VivaVision Biotech is a clinical-stage R&D biopharmaceutical company that is developing novel medicines to treat topical diseases. VivaVision Biotech is dedicated to bringing new therapeutics to millions of patients suffering from chronic ocular or dermal inflammatory diseases.

Forerunner Medical

Series B in 2021
Forerunner Medical (Shanghai) Co., Ltd., established in 2009, specializes in the development and manufacturing of innovative medical devices aimed at minimally invasive treatments. The company focuses on creating low-temperature plasma radio-frequency generators and electrodes specifically designed for sports medicine and tumor treatment. By leveraging extensive domestic clinical data and advanced technology, Forerunner Medical aims to meet both domestic and global healthcare needs. The organization emphasizes the quality and safety of its products, ensuring high performance, aesthetic appeal, and user convenience. Its commitment to excellence is reflected in its state-of-the-art production equipment and professional expertise, which contribute to its competitive advantage in the medical device industry.

Orient Speech Therapy

Series C in 2021
Orient Speech Therapy Center specializes in providing professional speech and language therapy services for children facing communication challenges, including those with autism or speech disorders. The center focuses on the early screening, clinical diagnosis, and therapeutic interventions essential for improving children's speech and social skills. It offers a range of refined curricula designed specifically for young learners, including the Star Curriculum, phonics and oral muscle courses, expression courses, and exercise classes. Through these structured programs, Orient Speech Therapy Center aims to enhance the communicative abilities of children, enabling them to express themselves more effectively and engage socially.

Bang Er Orthopedic

Series D in 2021
Zhejiang Bang Er Medical Investment Management Co., Ltd. is a prominent operator of hospitals specializing in orthopedic care and rehabilitation services, established in 2012 in Zhejiang Province, China. The company focuses on the diagnosis and treatment of various orthopedic conditions, including trauma-related injuries, hand and foot surgery, spine surgery, and joint surgery. By offering a comprehensive range of services, Bang Er aims to provide patients with the necessary care and treatment options for their orthopedic ailments, positioning itself as a key player in the healthcare sector of the Yangtze River Delta.

Weimai

Series C in 2020
Weimai is a developer of a health application platform that aims to enhance medical and health services. The platform offers various features, including Internet-based appointment scheduling, maternal and child disease management, grading diagnosis and treatment, remote diagnosis, and medical records management. By cooperating with local hospitals, Weimai provides a range of services such as medical consultations, internet diagnosis and treatment, health management, and on-site medical and nursing assistance. This integration not only facilitates access to medical care for patients but also helps hospitals improve their operational efficiency. Ultimately, Weimai's goal is to deliver a comprehensive family doctor application that brings medical expertise into homes.

Unionlab

Series A in 2020
Unionlab provides clinical CRO services with a focus on the field of oncology. Unionlab delivers an integrated service from the strategy to implementation, including strategy consultation, medical affairs, clinical study operation, third-party independent imaging review, data management, bioanalysis, FSP, and other related services.

Baikemy.com

Series B in 2019
Baikemy.com is a health encyclopedia based in Beijing, China, dedicated to providing authoritative healthcare information to its users. The platform serves as a scientific resource for the dissemination and exchange of medical knowledge, featuring a range of content including scientific articles, medical videos, and mutual aid communities. By collaborating with top-tier hospitals, Baikemy.com produces high-quality knowledge products that enhance users' understanding of healthcare. Through its comprehensive online medical information platform, the company aims to empower individuals with accessible and reliable health information, facilitating informed decision-making regarding their health and well-being.

Weimai

Series C in 2019
Weimai is a developer of a health application platform that aims to enhance medical and health services. The platform offers various features, including Internet-based appointment scheduling, maternal and child disease management, grading diagnosis and treatment, remote diagnosis, and medical records management. By cooperating with local hospitals, Weimai provides a range of services such as medical consultations, internet diagnosis and treatment, health management, and on-site medical and nursing assistance. This integration not only facilitates access to medical care for patients but also helps hospitals improve their operational efficiency. Ultimately, Weimai's goal is to deliver a comprehensive family doctor application that brings medical expertise into homes.

Phoebus Medical Technology

Series A in 2018
Phoebus Medical Technology is a healthcare company that specializes in developing an AI-driven chronic disease management platform. This platform is designed for professional disease monitoring, with a particular focus on diabetic retinopathy. By utilizing artificial intelligence technology, Phoebus Medical Technology aims to enhance the monitoring and management of chronic diseases, offering innovative solutions to treatment institutions. The company's mission is to provide reliable technological support that improves the quality of care for patients with chronic conditions.

Weimai

Series B in 2018
Weimai is a developer of a health application platform that aims to enhance medical and health services. The platform offers various features, including Internet-based appointment scheduling, maternal and child disease management, grading diagnosis and treatment, remote diagnosis, and medical records management. By cooperating with local hospitals, Weimai provides a range of services such as medical consultations, internet diagnosis and treatment, health management, and on-site medical and nursing assistance. This integration not only facilitates access to medical care for patients but also helps hospitals improve their operational efficiency. Ultimately, Weimai's goal is to deliver a comprehensive family doctor application that brings medical expertise into homes.

Sport With Fun

Angel Round in 2018
Sport With Fun is a sports and events photography company that provides photography services for sporting events.

Luqa Pharmaceuticals

Series B in 2018
Luqa Pharmaceuticals Co., Ltd. is a specialty pharmaceutical company based in Central, Hong Kong, that focuses on the development and commercialization of innovative healthcare products primarily for the Chinese market. Established in 2010, Luqa offers a diverse portfolio that includes dermatological and gastrointestinal products. Its dermatology line features Ebernet, a cream for fungal skin infections, and Strataderm, a silicone gel for scar treatment and prevention. In the gastrointestinal and oral care sectors, Luqa provides Lacteol, a probiotic for vulnerable patients, and GelX, a medical device for oral cavity lesions. Additional offerings include GelX Xero for dry mouth relief and Aftacure for treating oral mucosa irritations. The company also markets Ialuxid Gel for post-surgical wounds and Podofilm for benign epithelial formations. Luqa Pharmaceuticals aims to enhance the quality of life for patients by delivering effective solutions to prescribers and healthcare providers across China, Hong Kong, and Macau.

Virtus Medical Holding

Venture Round in 2018
Virtus Medical Holding is a healthcare provider that offers a comprehensive range of outpatient medical services, catering to individuals at various stages of their health journey. The company focuses on integrating high-end specialists with state-of-the-art facilities to deliver services such as physiotherapy, surgery, vaccination, and wellness and rehabilitation. Virtus emphasizes patient-centered care coordination through the establishment of an integrated medical tower, a custom clinic management system, and a dedicated health consultant team. This holistic approach ensures that patients receive seamless care, from wellness and prevention to treatment and rehabilitation, in a single, convenient location.

Vivace Therapeutics

Series B in 2017
Vivace Therapeutics, Inc. is a biotechnology company focused on the discovery and development of small molecule therapies aimed at treating cancer. Founded in 2014 and located in the San Francisco Bay Area, the company specializes in targeting the Hippo pathway, which plays a critical role in regulating tissue regeneration and organ size. Vivace Therapeutics employs an innovative approach by leveraging research from leading academic institutions to develop novel therapeutics that can be used independently or in combination with existing treatments. The company is committed to advancing promising drug candidates and therapeutic technologies to address the unmet needs of cancer patients, driven by a mission to improve patient outcomes and quality of life.

LinkDoc

Series B in 2016
LinkDoc Technology Limited, founded in 2014 and headquartered in Beijing, China, specializes in developing medical data solutions and big data platforms focused on oncology. The company provides clinical structured data services to oncology hospitals, enabling them to address scientific and clinical challenges effectively. LinkDoc is dedicated to offering continuous care for patients with critical diseases and delivers data-driven precision life sciences solutions that facilitate clinical research and enhance real-world adoption for life sciences companies and healthcare providers. Additionally, LinkDoc ensures that its private hospital deployments comply with US HIPAA Act standards, implementing robust security measures to protect patient privacy and data integrity.

AoHua

Series C in 2016
Aohua is a global provider of endoscopy devices and solutions, focused on advancing endoscope technology and enhancing diagnostic and treatment capabilities in endoscopy. Founded in 1994 and based in Shanghai, China, the company specializes in the research, development, production, and sales of electronic endoscope equipment, along with associated diagnostic and surgical consumables. Aohua aims to lead innovation in endoscopic technology, contributing to the overall progress of medical endoscopy practices.

ASLAN Pharmaceuticals

Series C in 2015
ASLAN Pharmaceuticals, established in 2010 and based in Singapore, is a clinical-stage biopharmaceutical company focused on immunology and oncology. It develops innovative treatments, including a monoclonal therapy for atopic dermatitis and a small molecule inhibitor for cancer, aiming to transform patients' lives. The company collaborates with prominent pharmaceutical partners and operates as a subsidiary of ASLAN Pharmaceuticals Limited.

Yaoshi Quanyun Jiankang

Angel Round in 2015
Yaoshi Quanyun Jiankang is a cloud platform for claiming health insurance policies.

INNOMED

Series A in 2015
Innomed engages in the development and manufacturing of interventional and implantable medical devices. The company's team has a wide range of skills, including developing and discovering new medical devices, using cutting-edge implantable materials, designing and evaluating products, optimizing manufacturing processes, implementing quality, clinical, and regulatory standards, and managing and developing staff.

Juliye

Series A in 2015
Juliye Care is a medical and healthcare service platform that focuses on integrating the medical supply chain and managing chronic diseases. The company connects patients with healthcare resources, facilitating access to essential services. Juliye Care serves hundreds of thousands of patients across various cities and regions, addressing their practical healthcare needs effectively.

Etong Health

Series A in 2015
Etong Health is a provider of healthcare management services that caters to large and medium-sized enterprises. The company offers a comprehensive online health management platform that includes various services such as physical examinations, health assessments, and health interventions. Additionally, Etong Health provides health-related education and consultation services, allowing clients to benefit from a one-stop solution for their health management needs. Their offerings encompass personal and group physical examinations, health management, and human resources services, ensuring that organizations can effectively manage the health and well-being of their employees.

Etong Healthcare

Series A in 2015
EtongOnline Shanghai Medical Consulting provides third-party health management services to large and medium-sized enterprises in Shanghai, Beijing, Shenzhen, Guangzhou, Wuhan, & Chengdu. Its healthy management services include file recording, health assessment, health intervention, health education, health consultation, and private doctor services. The company also provides health examination services, such as employment health check, physical examination, PET-CT testing, gene detection, and enterprise welfare health check services. In addition, it offers medical services, such as medical guidance, specialist appointment, admission solutions, surgery appointment, secondary consultation, and particular examination arrangement services. Further, the company provides services in the areas of establishment of health infirmary, enterprise stratified health management, overseas medical, medical tourism, liability insurance, and oral care. EtongOnline Shanghai Medical Consulting was founded in 2009 and is headquartered in Shanghai City, China.

IMPACT Therapeutics

Series A in 2014
IMPACT Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics for cancer and other life-threatening diseases. Founded in 2009 and based in Shanghai, China, the company focuses on creating targeted anti-cancer treatments utilizing synthetic lethality. IMPACT Therapeutics is actively engaged in several research and development projects, including a PARP inhibitor, a Wee1 inhibitor, and various novel agents targeting DNA damage response mechanisms and the Hedgehog signaling pathway. Through its commitment to advancing treatment options, IMPACT Therapeutics aims to provide patients with effective and targeted anti-cancer therapies.

ASLAN Pharmaceuticals

Series B in 2013
ASLAN Pharmaceuticals, established in 2010 and based in Singapore, is a clinical-stage biopharmaceutical company focused on immunology and oncology. It develops innovative treatments, including a monoclonal therapy for atopic dermatitis and a small molecule inhibitor for cancer, aiming to transform patients' lives. The company collaborates with prominent pharmaceutical partners and operates as a subsidiary of ASLAN Pharmaceuticals Limited.

fUGAO

Series B in 2013
fUGAO is a medical information system solutions provider company.

AoHua

Series A in 2013
Aohua is a global provider of endoscopy devices and solutions, focused on advancing endoscope technology and enhancing diagnostic and treatment capabilities in endoscopy. Founded in 1994 and based in Shanghai, China, the company specializes in the research, development, production, and sales of electronic endoscope equipment, along with associated diagnostic and surgical consumables. Aohua aims to lead innovation in endoscopic technology, contributing to the overall progress of medical endoscopy practices.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.